Carlo Toniatti

Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors.

Uwe Koch, Michael Rowley, U. Koch, 2009, Bioorganic & medicinal chemistry letters.

Oncology drug discovery: planning a turnaround.

Giulio Draetta, C. Toniatti, G. Draetta, 2014, Cancer discovery.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

L. Kwong, S. Kopetz, G. Powis, 2016, Oncotarget.

Electro-Gene-Transfer: A New Approach for Muscle Gene Delivery

Gennaro Ciliberto, G. Ciliberto, C. Toniatti, 2002, Somatic cell and molecular genetics.

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Wenjun Chang, Likun Li, Spyridon Basourakos, 2017, Science Signaling.

MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation

Li Wang, Thomas Buchholz, Carolyn Buser-Doepner, 2012, Investigational New Drugs.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Michael Peyton, Humam Kadara, Murim Choi, 2015, Cancer discovery.